Rivfloza

nedosiran

Approval

ApplicationNDA 215842
Approval dateSep 29, 2023
Approval year2023
SponsorNovo

FDA-approved use

To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Rivfloza: